Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients.

Speeckaert MM, Devreese KM, Vanholder RC, Dhondt A.

Nephrol Dial Transplant. 2013 Dec;28(12):3090-5. doi: 10.1093/ndt/gft293. Epub 2013 Sep 10.

PMID:
24021678
2.

Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis.

Kalicki RM, Aregger F, Alberio L, Lämmle B, Frey FJ, Uehlinger DE.

Thromb Haemost. 2007 Dec;98(6):1200-7.

PMID:
18064314
3.

Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?

Fiaccadori E, Maggiore U, Regolisti G.

Nephrol Dial Transplant. 2013 Dec;28(12):2923-8. doi: 10.1093/ndt/gft334. Epub 2013 Sep 11. No abstract available.

PMID:
24026242
4.

Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study.

Sombolos KI, Fragia TK, Gionanlis LC, Veneti PE, Bamichas GI, Fragidis SK, Georgoulis IE, Natse TA.

Int J Clin Pharmacol Ther. 2008 Apr;46(4):198-203.

PMID:
18397694
5.

Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation.

Mahieu E, Claes K, Jacquemin M, Evenepoel P, Op De Beek K, Bogaert AM, Kuypers D, Verhamme P, Meijers B.

Artif Organs. 2013 May;37(5):482-7. doi: 10.1111/aor.12002. Epub 2013 Mar 5.

PMID:
23461610
6.

Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.

Sánchez-Canel JJ, Pons-Prades R, Salvetti ML, Seores A, Vázquez M, Pérez-Alba A, Tamarit E, Calvo-Gordo C, Villatoro J.

Nefrologia. 2012;32(5):605-12. doi: 10.3265/Nefrologia.pre2012.Jun.11486. English, Spanish.

7.

Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets.

Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Brosstad F.

Nephrol Dial Transplant. 2001 May;16(5):987-93.

PMID:
11328905
8.

Haemodialysis in patients treated with oral anticoagulant: should we heparinize?

Krummel T, Scheidt E, Borni-Duval C, Bazin D, Lefebvre F, Nguyen P, Hannedouche T.

Nephrol Dial Transplant. 2014 Apr;29(4):906-13. doi: 10.1093/ndt/gft522. Epub 2014 Jan 23.

PMID:
24459138
9.

Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.

Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J.

Nephrol Dial Transplant. 2003 Oct;18(10):2097-104.

PMID:
13679486
10.

A single dose of dalteparin effectively prevents clotting during haemodialysis.

Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Fauchald P, Brosstad F.

Nephrol Dial Transplant. 1999 Aug;14(8):1943-7.

PMID:
10462275
11.

Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.

Frank RD, Müller U, Lanzmich R, Groeger C, Floege J.

Nephrol Dial Transplant. 2006 Apr;21(4):1013-8. Epub 2005 Dec 2.

PMID:
16326745
12.

Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.

Anderson JA, Hirsh J, Yusuf S, Johnston M, Afzal R, Mehta SR, Fox KA, Budaj A, Eikelboom JW.

J Thromb Haemost. 2010 Feb;8(2):243-9. doi: 10.1111/j.1538-7836.2009.03705.x. Epub 2009 Nov 26.

13.

Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.

Verhave G, Weijmer MC, van Jaarsveld BC.

Neth J Med. 2015 Jul;73(6):270-5.

14.

Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.

Klingel R, Schaefer M, Schwarting A, Himmelsbach F, Altes U, Uhlenbusch-Körwer I, Hafner G.

Nephrol Dial Transplant. 2004 Jan;19(1):164-70.

PMID:
14671052
15.

Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin.

Pauwels R, Devreese K, Van Biesen W, Eloot S, Glorieux G, Vanholder R, Dhondt A.

Nephrol Dial Transplant. 2014 May;29(5):1092-6. doi: 10.1093/ndt/gft508. Epub 2013 Dec 22.

PMID:
24366900
16.

[Anticoagulation of the extracorporeal circuit in chronic hemodialysis].

Ryckelynck JP, Chouraqui D, Lobbedez T.

Nephrologie. 1998;19(4):223-5. Review. French.

PMID:
9675763
17.

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

Becattini C, Vedovati MC, Agnelli G.

Thromb Res. 2012 Mar;129(3):392-400. doi: 10.1016/j.thromres.2011.12.014. Epub 2012 Jan 20. Review.

PMID:
22264937
18.

Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy.

Cope J, Bushwitz J, An G, Antigua A, Patel A, Zumberg M.

Ann Pharmacother. 2015 Mar;49(3):270-7. doi: 10.1177/1060028014563325. Epub 2014 Dec 16.

PMID:
25515864
19.

[The risk of bleeding associated with low molecular weight heparin in patients with renal failure].

Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.

G Ital Nefrol. 2010 Nov-Dec;27(6):649-54. Italian.

PMID:
21132647
20.

Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.

Kessler M, Gangemi C, Gutierrez Martones A, Lacombe JL, Krier-Coudert MJ, Galland R, Kielstein JT, Moureau F, Loughraieb N.

Hemodial Int. 2013 Apr;17(2):282-93. doi: 10.1111/j.1542-4758.2012.00733.x. Epub 2012 Aug 23.

PMID:
22925178

Supplemental Content

Support Center